These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 16304401

  • 1. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV.
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [Abstract] [Full Text] [Related]

  • 2. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L, Gutiérrez NC, Vidriales MB, Mateos MV, Rasillo A, García-Sanz R, Paiva B, San Miguel JF.
    Clin Cancer Res; 2011 Apr 01; 17(7):1692-700. PubMed ID: 21325290
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Rajkumar SV, Lacy MQ, Kyle RA.
    Blood Rev; 2007 Sep 01; 21(5):255-65. PubMed ID: 17367905
    [Abstract] [Full Text] [Related]

  • 4. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.
    Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, Grosbois B, Bataille R.
    Blood; 1999 Oct 15; 94(8):2583-9. PubMed ID: 10515861
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L, Fernández de Larrea C, Elena M, Cibeira MT, Tovar N, Aróstegui JI, Pedrosa F, Rosiñol L, Filella X, Yagüe J, Bladé J.
    Clin Lymphoma Myeloma Leuk; 2016 Jun 15; 16(6):e71-7. PubMed ID: 27013181
    [Abstract] [Full Text] [Related]

  • 6. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
    Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R.
    Cancer Res; 1999 Sep 15; 59(18):4546-50. PubMed ID: 10493504
    [Abstract] [Full Text] [Related]

  • 7. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM, UK Myeloma Forum.
    Haematologica; 2009 Dec 15; 94(12):1708-13. PubMed ID: 19996118
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV.
    Hematol Oncol Clin North Am; 2014 Oct 15; 28(5):775-90. PubMed ID: 25212882
    [Abstract] [Full Text] [Related]

  • 9. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
    Kaufmann H, Ackermann J, Baldia C, Nösslinger T, Wieser R, Seidl S, Sagaster V, Gisslinger H, Jäger U, Pfeilstöcker M, Zielinski C, Drach J.
    Leukemia; 2004 Nov 15; 18(11):1879-82. PubMed ID: 15385925
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.
    Int J Lab Hematol; 2016 May 15; 38 Suppl 1():110-22. PubMed ID: 27161311
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J, Moehler T, Hundemer M.
    Recent Results Cancer Res; 2011 May 15; 183():113-31. PubMed ID: 21509683
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV, Landgren O.
    Cancer Treat Res; 2016 May 15; 169():3-12. PubMed ID: 27696254
    [Abstract] [Full Text] [Related]

  • 16. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW.
    Blood; 2002 Aug 15; 100(4):1417-24. PubMed ID: 12149226
    [Abstract] [Full Text] [Related]

  • 17. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR.
    Clin Cancer Res; 2002 Jul 15; 8(7):2210-6. PubMed ID: 12114422
    [Abstract] [Full Text] [Related]

  • 18. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
    Dong L, Chen CY, Ning B, Xu DL, Gao JH, Wang LL, Yan SY, Cheng S.
    Genet Mol Res; 2015 Aug 14; 14(3):9571-84. PubMed ID: 26345890
    [Abstract] [Full Text] [Related]

  • 19. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.
    Weiss BM, Kuehl WM.
    Expert Rev Hematol; 2010 Apr 14; 3(2):165-74. PubMed ID: 20473362
    [Abstract] [Full Text] [Related]

  • 20. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA, Rajkumar SV.
    Oncology (Williston Park); 2011 Jun 14; 25(7):578-86. PubMed ID: 21888255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.